Tags : Janssen Pharmaceutical

Janssen Reports Five-Year Data of Stelara (ustekinumab) in P-lll LTE

Shots: The P-lll IM-UNITI LTE study involves assessing of Stelara (SC, 90mg, q8w/q12w) vs PBO as maintenance therapy in 1,281 patients with moderate to severe CD. All patients completing 44wks. were eligible to enter the LTE program, continuing their current regimen ~252wks. 50%+ patients were randomized to q8w dosing and continued to receive this dosage […]Read More